Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through platelet-cycloxygenase inhibition

Table 4 2017 Clinical, Laboratory, Molecular and Pathobiological classification and staging of JAK2V617F trilinear Myeloproliferative Neoplasms: Therapeutic Implications

PV: CLMP stage	0	1	2	3	4	5	6
Clinical Diagnosis	Prodromal PV	Erythrocythemia	Early PV	Classical PV	Masked advanced PV	Inapparent PV: IPV → Spent phase	Post-PV MF
LAP-score, CD11B	↑	↑	↑	↑	↑/↑↑	↑	Variable
EEC	+	+	+	+	+	+	+
Red CELL MASS	N	N	↑	↑/↑↑	↑/↑↑	↑ N or ↓	Variable
Erythrocytes × 1012/L	< 5.8	> 5.8	> 5.8	> 5.8	N	N	↓
Leukocytes × 109/L	< 12	< 12	< or > 12	< or-> 15	> 15	N or ↑	> 20
Platelets × 109/L	> 400	400	< or > 400	> 400	+1000	N or ↑	Variable
Bone marrow histology	EM	EM	EM	EMG	EMG	MG-MF	MF
BM cellularity (%)	50-80	50-80	60-100	80-100	80-100	60-100	↓
Grading RF	RF 0-1	RF 0-1	RF 0-1	RF 0/1	RCF2/3	RCF 2/3	RCF 3/4
Grading MF57	MF 0	MF 0	MF 0	MF 0	MF 1 2	MF 1 2	MF 2/3
Spleen size:
On echogram	< 12-15	< 13	12-15	12-16	18- > 20	16 > 20	> 20 cm
Below MCL	0-3	NP	0-3	4-6	> 6	> 6	> 8 cm
JAK2V617F load	Low +(++)	low +(++)	Moderate < 50% +	Mod/High + / ++	High > 50% ++	High → 50% ++	High → 50% ++
Granulocytes %
Risk stratification → Therapeutic implications according to guidelines	Low	Low	Low	Inter- mediate	High early MF	JAK2 inhibitor	Post-PV MF
			Moderate

Source Michiels et al[68,70,80] 2006, 2017. ↑: Increased; ↓: Decreased; N: Normal; +: Present or heterozygous; ++: Homozygous; RCT: Randomized clinical trial; ET: Essential thrombocythemia; PV: Polycythemia vera.